Biogen Secures FDA Nod for High-Dose SPINRAZA Regimen in SMA Treatment
Event summary
- FDA approved Biogen’s High Dose Regimen of SPINRAZA (nusinersen) for spinal muscular atrophy (SMA) on March 30, 2026.
- The approval was based on data from the Phase 2/3 DEVOTE study, showing significant motor function improvements in treatment-naïve infants.
- High Dose SPINRAZA will be available in the U.S. in the coming weeks and is also approved in the EU, Switzerland, and Japan.
- The new regimen includes an accelerated loading phase with 50 mg doses and a 28 mg maintenance dose every four months.
The big picture
Biogen’s FDA approval for the High Dose Regimen of SPINRAZA reinforces its leadership in SMA treatment, addressing unmet needs in a competitive landscape. The approval comes as the biotech industry continues to innovate in rare disease therapies, with a focus on optimizing dosing and efficacy. Biogen’s ability to leverage its decade-long clinical data on SPINRAZA positions it to maintain market share amid rising competition.
What we're watching
- Market Penetration
- The pace at which Biogen can transition existing SPINRAZA patients to the High Dose Regimen and attract new patients.
- Competitive Dynamics
- Whether the High Dose Regimen can differentiate SPINRAZA from competitors like Roche’s risdiplam and Novartis’s Zolgensma.
- Regulatory Expansion
- The speed at which Biogen secures approvals for the High Dose Regimen in additional global markets.
Related topics